FDA grants fast track designation for enobosarm in AR+ ER+ HER2- metastatic breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA granted Fast Track designation to the phase III registration program for enobosarm, a selective androgen receptor targeting agonist, for the treatment of androgen receptor positive, estrogen receptor positive, human epidermal growth factor receptor 2 negative (AR+ER+HER2-) metastatic breast cancer patients who have shown previous disease progression on a nonsteroidal AI, Faslodex (fulvestrant), and CDK 4/6 inhibitor therapy, and who have AR% nuclei staining ≥40% in breast cancer tissue (third-line metastatic setting).

Enobosarm is sponsored by Veru Inc. 

Enobosarm is in clinical development for three indications: 

  • A phase III ARTEST clinical study, which is enrolling, evaluating enobosarm for the treatment of third-line metastatic AR+ER+HER2- breast cancer patients whose disease has progressed after treatment with a nonsteroidal aromatase inhibitor, Faslodex, and a CDK4/6 inhibitor with an androgen receptor nuclei staining of ≥40%.
  • Planned phase III ENABLAR-2 clinical study evaluating enobosarm + Verzenio (abemaciclib) combination therapy as treatment of second-line metastatic AR+ER+HER2- breast cancer patients whose breast cancer has progressed after treatment with Ibrance (palbociclib) and either a nonsteroidal aromatase inhibitor or Faslodex combination with an androgen receptor nuclei staining of ≥40%. 
  • A planned phase II clinical study of Veru’s enobosarm + sabizabulin combination therapy in metastatic triple negative breast cancer after two systemic chemotherapies.
Table of Contents

YOU MAY BE INTERESTED IN

When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.

Login